What is he best known for?
The fields of study he is best known for:
- Cancer
- Internal medicine
- Gene
Geoffrey Liu focuses on Internal medicine, Lung cancer, Cancer, Oncology and Odds ratio.
His Internal medicine study combines topics from a wide range of disciplines, such as Gastroenterology, Allele and Pathology.
Geoffrey Liu combines subjects such as Respiratory disease, Surgery, Immunology, Carcinoma and Genotype with his study of Lung cancer.
His Immunology research incorporates elements of Body mass index, Haplotype and Hazard ratio.
His biological study spans a wide range of topics, including DNA Mutational Analysis, Plasma cell, Cancer research, DNA methylation and Family history.
Geoffrey Liu interconnects Geriatric assessment, Allele frequency, Epidermal growth factor receptor and Risk factor in the investigation of issues within Oncology.
His most cited work include:
- A susceptibility locus for lung cancer maps to nicotinic acetylcholine receptor subunit genes on 15q25 (1074 citations)
- Ceritinib in ALK-Rearranged Non–Small-Cell Lung Cancer (1073 citations)
- Patient preferences for oral versus intravenous palliative chemotherapy. (807 citations)
What are the main themes of his work throughout his whole career to date?
Internal medicine, Oncology, Lung cancer, Cancer and Odds ratio are his primary areas of study.
His Internal medicine research includes elements of Gastroenterology and Genotype.
His Oncology study incorporates themes from Single-nucleotide polymorphism, Proportional hazards model and Bioinformatics.
The study incorporates disciplines such as Respiratory disease, Cancer research, Surgery, Immunology and Carcinoma in addition to Lung cancer.
Geoffrey Liu has included themes like Logistic regression, Smoking cessation, Family medicine, Disease and Physical therapy in his Cancer study.
His Odds ratio research includes themes of Case-control study and Allele.
He most often published in these fields:
- Internal medicine (69.21%)
- Oncology (45.92%)
- Lung cancer (35.96%)
What were the highlights of his more recent work (between 2019-2021)?
- Internal medicine (69.21%)
- Oncology (45.92%)
- Lung cancer (35.96%)
In recent papers he was focusing on the following fields of study:
His primary areas of investigation include Internal medicine, Oncology, Lung cancer, Cancer and Cancer research.
His Internal medicine study combines topics in areas such as Mendelian randomization and Genome-wide association study.
His Oncology study also includes fields such as
- Single-nucleotide polymorphism which connect with Genetic variation,
- Risk factor together with Case-control study.
In Lung cancer, Geoffrey Liu works on issues like Adenocarcinoma, which are connected to Lung.
His Cancer research is multidisciplinary, relying on both Alcohol consumption, Logistic regression, Smoking cessation and Patient education.
His Cancer research study combines topics in areas such as Cell culture and Drug resistance.
Between 2019 and 2021, his most popular works were:
- First-Line Lorlatinib or Crizotinib in Advanced ALK-Positive Lung Cancer (30 citations)
- Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. (24 citations)
- Organoid Cultures as Preclinical Models of Non-Small Cell Lung Cancer. (24 citations)
In his most recent research, the most cited papers focused on:
- Cancer
- Internal medicine
- Gene
His primary areas of study are Internal medicine, Lung cancer, Oncology, Hazard ratio and Cancer research.
His Internal medicine research focuses on Single-nucleotide polymorphism and how it relates to Mendelian randomization.
His work carried out in the field of Lung cancer brings together such families of science as Body mass index, Allele, Lung cancer susceptibility, Cohort and Adenocarcinoma.
His Oncology research is multidisciplinary, relying on both Cancer, Obesity, Incidence, Confidence interval and Risk factor.
The study incorporates disciplines such as Overweight, Underweight, Antibody and Proportional hazards model in addition to Hazard ratio.
His Cancer research research is multidisciplinary, incorporating elements of Anaplastic lymphoma kinase, Crizotinib, Alectinib, Carcinoma and microRNA.
This overview was generated by a machine learning system which analysed the scientist’s
body of work. If you have any feedback, you can
contact us
here.
